Example: quiz answers
Reflection Paper Expectations Electronic Source Data Data ...
Working Group. The paper is intended to cover the creation/capture of electronic clinical data in all clinical trials in the EU/EEA or in third countries in case the clinical trial reports are submitted as part of Marketing Authorisation Applications to EU/EEA regulatory authorities. The requirements have their basis in Directive 2001/20/EC
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
European Medicines Agency Policy Publication Clinical Data ...
www.ema.europa.eu• Clinical data (either data provided to the Agency before 1 January 2015 or data not yet held by the Agency) submitted to the Agency for non-centrally authorised products . These clinical data continue to be made available to external requesters on a reactive basis in accordance with the aforementioned Agency’s policy on access to documents .
CLINICAL REASONING (is this just one part of the process
www.utas.edu.auclinical problem that needs immediate attention and one that is less acute (del Bueno, 1994); and a tendency to make errors in time sensitive situations where there is a large amount of complex data to process (O‟Neill, 1994). In clinical practice experienced nurses engage in multiple clinical reasoning episodes for each patient in their care.